PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, your source for the latest clinical literature updates. Today, we’re discussing recent Phase 2 trials evaluating deucravacitinib in inflammatory bowel disease, specifically Crohn’s disease and ulcerative colitis. Seth, great to have you here.
Seth: Thanks, Britany. Deucravacitinib, a selective TYK2 inhibitor, has drawn interest due to its oral administration and targeted mechanism. Let’s start with some background on IBD and why this drug was promising.
Britany: Crohn’s disease and ulcerative colitis cause chronic relapsing inflammation of the GI tract. Moderate to severe cases often need immunomodulators or biologics, but there’s a need for effective oral therapies with good safety profiles.
Seth: The pathophysiology involves dysregulated immune signaling, with interleukin-23 (IL-23) playing a key role. TYK2 mediates IL-23 receptor signaling, making it a logical target. Deucravacitinib selectively inhibits TYK2, potentially reducing inflammation.
Britany: That selectivity is important. Unlike broader Janus kinase inhibitors, deucravacitinib’s selective inhibition might mean fewer adverse events. It’s already effective in psoriasis, which encouraged its use in IBD.
Seth: Before these Phase 2 trials, clinical data on TYK2 inhibition in IBD were limited. These studies aimed to evaluate deucravacitinib’s efficacy and safety in moderate to severe Crohn’s and ulcerative colitis.
Britany: The design included three randomized, double-blind, placebo-controlled Phase 2 trials: two in Crohn’s disease—LATTICE-CD and IM011-127—and one in ulcerative colitis, LATTICE-UC.
Seth: There were 408 patients total—239 with Crohn’s and 169 with ulcerative colitis. Adults had confirmed moderate to severe disease by clinical indices and endoscopy.
Britany: Patients with recent biologic use, active infections, or comorbidities limiting immunosuppression were excluded to ensure a homogeneous population.
Seth: Deucravacitinib was given orally at 3 mg, 6 mg, or 12 mg twice daily, compared to placebo. The induction period lasted 12 weeks.
Britany: Primary endpoints were clinical remission and response at week 12. Secondary endpoints included endoscopic response and remission, biomarker changes like CRP and fecal calprotectin, plus safety assessments.
Seth: Analyses were intention-to-treat, comparing outcomes versus placebo with chi-square tests. Subgroup analyses by dose and disease subtype were also done.
Britany: Patient demographics were balanced, with average age 35–45 years and roughly equal gender distribution, typical for IBD populations.
Seth: Disease activity was moderate to severe with endoscopic confirmation, reflecting real-world candidates for advanced therapies.
Britany: Now, the key findings: the primary efficacy endpoints were not met. Deucravacitinib did not show significant clinical remission or response compared to placebo at 12 weeks.
Seth: A high placebo response rate complicated detection of drug effects. In LATTICE-CD, the 3 mg twice daily dose showed significant endoscopic response, but this didn’t translate into clinical remission.
Britany: Both LATTICE-CD and IM011-127 trials were terminated early due to lack of efficacy signals. However, safety data were reassuring; deucravacitinib was well tolerated with no new safety concerns.
Seth: This safety profile aligns with prior studies in psoriasis and other conditions, suggesting selective TYK2 inhibition is generally safe, though efficacy in IBD remains uncertain.
Britany: Other IL-23 pathway agents like risankizumab have shown robust Phase 3 efficacy in Crohn’s and ulcerative colitis, blocking the IL-23p19 subunit upstream and improving clinical and biomarker outcomes.
Seth: Risankizumab’s success confirms IL-23 as a valid target. Deucravacitinib’s failure may relate to the molecule, dosing, or downstream TYK2 inhibition rather than pathway relevance.
Britany: This raises questions about whether dosing was optimal or if longer treatment might yield different results. The 12-week induction may have been too short to see benefit.
Seth: Also, high placebo responses suggest future trials need optimized designs, possibly with biomarker-driven patient selection or longer follow-up to better detect drug effects.
Britany: Regarding biomarkers, deucravacitinib didn’t significantly reduce CRP or fecal calprotectin, unlike risankizumab, which normalizes these markers. This questions deucravacitinib’s biological activity in IBD.
Seth: That’s a key clinical point. Biomarker changes can provide early efficacy signals before clinical remission.
Britany: On drug interactions, deucravacitinib is metabolized by cytochrome P450 enzymes, so strong CYP inhibitors or inducers like ketoconazole or rifampin could affect levels. Clinicians should be cautious.
Seth: Despite favorable safety, monitoring for interactions is essential, especially in complex IBD patients on multiple meds.
Britany: Special populations were excluded—those with recent biologic use or significant comorbidities—so data are limited. Real-world patients often have prior biologic exposure or other health issues that could affect outcomes.
Seth: That’s a limitation. Future studies should explore deucravacitinib in biologic-experienced patients and those with comorbidities to better define its role.
Britany: In summary, deucravacitinib was safe and well tolerated but didn’t show significant clinical benefit over placebo in moderate to severe Crohn’s or ulcerative colitis after 12 weeks. High placebo response and early termination limit conclusions.
Seth: The data suggest targeting TYK2 downstream of IL-23 may be insufficient for remission induction, or dosing and trial design need refinement. IL-23p19 antibodies remain more effective for this pathway.
Britany: Clinicians should note deucravacitinib isn’t ready for routine IBD use, but its safety supports further research. Longer studies, higher doses, or combination therapies might unlock potential.
Seth: From a pharmacist’s view, understanding these nuances aids patient counseling and therapeutic decisions as new oral agents emerge.
Britany: Thanks for the insightful discussion, Seth. While deucravacitinib’s IBD journey has been challenging, the evolving targeted therapy landscape offers hope.
Seth: Thank you, Britany. Staying updated is key to optimizing IBD care.
Britany: That’s today’s PACULit update. For details, listeners can access the full study by D’Haens et al. in the Journal of Crohn’s and Colitis. Until next time, stay curious and advance clinical practice.
Seth: Take care, everyone!